Generic Name and Formulations:
Balsalazide disodium 1.1g; tabs; contains sodium 126mg/tab.
Valeant Pharmaceuticals, Inc
Indications for GIAZO:
Treatment of mildly-to-moderately active ulcerative colitis in male patients. Limitations of use: effectiveness in treatment of female patients was not demonstrated. Safety and effectiveness of therapy beyond 8 weeks have not been established.
≥18yrs: 3 tabs twice daily; max 8 weeks.
<18yrs: not established.
Monitor for worsening symptoms of ulcerative colitis. Discontinue if acute intolerance syndrome is suspected. Known or history of renal impairment. Monitor renal function prior to initating and periodically during therapy. Hepatic impairment; consider monitoring LFTs during therapy. Elderly. Pregnancy (Cat. B). Nursing mothers.
In male patients: anemia, diarrhea, pharyngolaryngeal pain, UTI.
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- AAP Shares List of 5 Unnecessary Pediatric Tests and Procedures
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity